

# Contemporary Thinking of Optimal Bifurcation PCI: Current State-of-the-Art

Yves Louvard, ICPS, Massy, Quincy,  
Générale de santé-Ramsay, France

**TCTAP 2018, Seoul, Korea**


**Bifurcation is life**  
*(and vice versa)*

**SB are over treated**

## All comers Provisional versus 2 stents randomized trials (n= 5)

	1 ary Endpoint	Syst. angio	Endpoint %	(Cardiac) death %	MI %	TVR %	TLR %	Rest.	ST
Nordic 2006 Circ.	<b>C. death MI ST TVR 6 m</b>	6 m	2.9	1	0	1.9			0.5
			3.4	1	0.5	1.9		0	
CACTUS 2009 Circ.	<b>C. death MI ST TVR 6 m</b>	8 m	15	0.5	8.6	6.2			Def 1.1
			15.8	0	10.7	6.8		1.7	
BBC 1 2010 Circ.	<b>Death MI TVF 9 m</b>	No	8	2	3.6	5.5			1
			15.1	1	11.2	7.2		5	
Lin 2010 Coron Art Dis	<b>C. death MI ST TVR 8 m</b>	8 m	38.9	0	1.9		<b>26.9</b>		1.9
			11	0	1.9		<b>6.4</b>	0	
PERFECT 2015 JACCI	<b>% restenosis 2 branch</b>	8 m	SB 8.3/3.9	0.5	14.1	3.4	3.4	11	0
			MB 4.8/5.2	0.9	14.1	2.9	1.9	8.4	0.5

# Choice of stenting strategy in true coronary artery bifurcation lesions



# Assessment of Clinical, Electrocardiographic, and **Physiological Relevance** of Diagonal Branch in Left Anterior Descending Coronary Artery Bifurcation Lesions

Bon-Kwon Koo, MD, PhD,\* Seung-Pyo Lee, MD,\* Ju-Hee Lee, MD,\*  
Kyung-Woo Park, MD, PhD,\* Jung-Won Suh, MD, PhD,† Young-Seok Cho, MD, PhD,†  
Woo-Young Chung, MD, PhD,‡ Joon-Hyung Doh, MD, PhD,§  
Chang-Wook Nam, MD, PhD,|| Cheol Woong Yu, MD, PhD,¶ Bong-Ki Lee, MD, PhD,#  
Dobrin Vassilev, MD,\*\* Robert Gil, MD,†† Hong-Seok Lim, MD, PhD,‡‡  
Seung-Jea Tahk, MD, PhD,‡‡ Hyo-Soo Kim, MD, PhD\*


*Seoul, Gyeonggi-do, Daegu, Bucheon, and Kangwŏn-do, Korea; Sofia, Bulgaria; and Warsaw, Poland*

**Revascularization for clinically insignificant side branches cannot be translated into clinical benefit and may even be harmful**

**What is a significant or (chronically) relevant SB ?**

## Which side branch deserves stent implantation?

- In terms of ischemia at risk, revascularization is better than medical treatment when moderate to severe ischemia exists. Therefore, it is important **to define the side branches that can cause  $\geq 10\%$  ischemia**





**How to recognized a relevant SB ?**

# Identification of Coronary Artery Side Branch Supplying Myocardial Mass That May Benefit From Revascularization

## Multivariate Generalized Estimating Equations Modeling for Prediction of %FMM >10%

	Odds Ratio ± SE	p Value
Side branch length ≥73 mm	41.9 ± 2.1	<0.001
Left main bifurcation	345.2 ± 2.9	<0.001
Reference vessel diameter ≥2.68 mm	1.5 ± 1.9	0.73
Left ventricular mass >104.8 g	1.4 ± 1.8	0.61
Fractional flow reserve <0.80	2.3 ± 2.2	0.24

Multivariate generalized estimating equations modeling was performed using optimal cutoffs of each parameters predicting FMM >10%. The respective c-statistics of left main bifurcation, reference vessel diameter >2.68 mm, left ventricular mass >104.8 g, and FFR <0.80 were 0.820, 0.734, 0.609, and 0.526 (p < 0.05, all)

## SNuH score

Variables	Description	Score
Size ( <b>S</b> )	Vessel diameter $\geq 2.5\text{mm}$	1
Number ( <b>Nu</b> )	Number of diagonal branches $\leq 2$	1
Highest ( <b>H</b> )	No branch below the target branch	1

Koo BK, et al., JACC Intv, 2012

## Modified SNUH (mSNUH) score

Variables	Description	Score
<b>Size</b>	Vessel diameter $\geq 2.5\text{mm}$	1
	Number of diagonal branches = 1	2
<b>Number</b>	Number of diagonal branches = 2	1
	Number of diagonal branches $\geq 3$	0
<b>Ubity</b>	Left dominant or Apical area reaching OM branch	-1*
<b>Highest</b>	No branch below the target branch in proximal to mid LAD	1

\*If total score is 0, then -1 is not added (The lowest total score is 0)

**Non relevant SB = SB wire protection**

**Single stenting better in majority of cases**

## Randomized trials in true non LM bifurcation lesions w large SB (n=3)

	Centers	Stent	1 / 2	True bif. %	SB	2 stents technique	Crossover 1:2 / 2:1
DKCRUSH-II 2011 JACC	7	Excel	185 / 185	100 / 100	>2.5, long L.	DK crush	28.6% / -
Nordic-Baltic IV 2013	16	Cypher Xience	221 / 229	100 / 100	>2.75	Culotte, ...	3.7% / 4%
EBC 2 2015	20	Nobori	103 / 97	100 / 100	> 2.5, long L.	Culotte	16% / 3%

## Randomized trials in true non LM bifurcation lesions w large SB (n=3)

	Centers	Stent	1 / 2	SB stenosis	SB	2 stents technique	Crossover 1:2 / 2:1
<b>DKCRUSH-II 2011 JACC</b>	7	Excel	185 / 185	63% / 63%	>2.5, long L.	DK crush	28.6% / -
<b>Nordic-Baltic IV 2013</b>	16	Cypher Xience	221 / 229	44% / 47%	>2.75	Culotte, ...	3.7% / 4%
<b>EBC 2 2015</b>	20	Nobori	103 / 97	? / ?	> 2.5	Culotte	16% / 3%


## Randomized trials in true non LM bifurcation lesions w large SB (n=3)

	<b>Centers</b>	<b>Stent</b>	<b>1 / 2</b>	<b>True bif. %</b>	<b>SB QCA diameter</b>	<b>2 stents technique</b>	<b>Crossover 1:2 / 2:1</b>
<b>DKCRUSH-II 2011 JACC</b>	7	Excel	185 / 185	100 / 100	<b>2.3 / 2.4</b>	DK crush	28.6% / -
<b>Nordic-Baltic IV 2013</b>	16	Cypher Xience	221 / 229	100 / 100	<b>2.4 / 2.5</b>	Culotte, ...	3.7% / 4%
<b>EBC 2 2015</b>	20	Nobori	103 / 97	100 / 100	? / ?	Culotte	16% / 3%




# Randomized study comparing Double Kissing Crush with Provisional Stenting for treatment of coronary bifurcation lesions: DK-CRUSH-II

## Comparison of Survival Rate Free From TLR Between DK Crush and PS Groups





## Two-year MACE



Number at risk		0	100	200	300	400	500	600	700
Two-stent tech.	228	221	221	214	212	211	209	206	
Provisional tech.	218	209	208	196	194	192	189	187	


**MACE:** cardiac death, non-procedural myocardial infarction, target lesion revascularization and definite stent thrombosis



• euro  
**PCR**  
**2015**


## The EBC TWO Trial

### 12 M Outcome : Death, MI and TVR at 12



# EBC 2012: stimulation era

## Provisional stenting strategy



## COBIS II POT Study: Clinical outcomes

- Patients with **SB diameter**  $\geq 2.5$  mm in core-lab QCA (N=1,191)
- Propensity score-matching population

	<b>POT</b> (n=204)	<b>No POT</b> (n=665)	<b>HR (95% CI)</b>	<b>p value</b>
<b>MACE</b>	<b>6 (2.9)</b>	<b>78 (11.7)</b>	<b>0.25 (0.11-0.60)</b>	<b>0.002</b>
<b>All-cause death</b>	7 (3.4)	25 (3.8)	0.97 (0.41-2.33)	0.95
<b>Cardiac death</b>	1 (0.5)	9 (1.4)	0.37 (0.05-2.97)	0.35
<b>Myocardial infarction</b>	0	12 (1.8)	-	-
<b>Stent thrombosis</b>	2 (1.0)	8 (1.2)	0.98 (0.20-4.77)	0.98
<b>TLR</b>	5 (2.5)	61 (9.2)	0.27 (0.10-0.69)	<b>0.006</b>
<b>MV, proximal</b>	<b>3 (1.5)</b>	<b>40 (6.0)</b>	<b>0.25 (0.07-0.82)</b>	<b>0.02</b>
<b>MV, distal</b>	<b>4 (2.0)</b>	<b>47 (7.1)</b>	<b>0.28 (0.10-0.80)</b>	<b>0.02</b>
<b>SB</b>	4 (2.0)	35 (5.3)	0.37 (0.13-1.09)	0.07
<b>Both vessels</b>	5 (2.5)	48 (7.2)	0.34 (0.13-0.88)	<b>0.03</b>

# Long-term Clinical outcomes of **final KB** in coronary bifurcation lesions treated with the **1-stent technique**: results from the COBIS II registry

## Clinical Outcomes in FKB Group Compared With Non-FKB Group in Propensity-Matched Population During FU Period


	FKB (n = 545)	Non-FKB (n = 545)	Unadjusted HR (95% CI)	p Value	Adjusted HR* (95% CI)	p Value
All-cause death	17 (3.1)	20 (3.7)	0.67 (0.30-1.48)	0.32	0.68 (0.28-1.63)	0.39
Cardiac death	3 (0.6)	8 (1.5)	0.43 (0.11-1.66)	0.22	0.50 (0.11-2.29)	0.37
MI	4 (0.7)	5 (0.9)	0.50 (0.09-2.73)	0.42	0.18 (0.01-20.36)	0.48
Stent thrombosis†	3 (0.6)	4 (0.7)	0.72 (0.16-3.23)	0.67	0.77 (0.17-3.45)	0.73
Target lesion revascularization	32 (5.9)	43 (7.9)	0.53 (0.30-0.94)	0.03	0.51 (0.28-0.91)	0.02
Main vessel	31 (5.7)	40 (7.3)	0.53 (0.30-0.96)	0.04	0.51 (0.28-0.93)	0.03
Side branch	12 (2.2)	18 (3.3)	0.57 (0.24-1.36)	0.21	0.57 (0.24-1.37)	0.21
Both vessels	23 (4.2)	38 (7.0)	0.47 (0.25-0.88)	0.02	0.47 (0.25-0.90)	0.02
MACE‡	37 (6.8)	53 (9.7)	0.54 (0.32-0.89)	0.02	0.50 (0.30-0.85)	0.01

\*Adjusted covariates include hypertension, history of coronary artery bypass graft, and distal RD of SB


## How to perform optimal Final Kissing?

- Optional for provisional, mandatory for complex techniques;
- Short & NC balloons, size according to distal reference;
- *Side branch first* (equal or alternate 12 atm vs. 4 atm);
- Simultaneous deflation;
- Longer inflation (at least 20-30 seconds);

Single stent: pre FKBI



Single stent: post FKBI




# Main technical options for elective double stent implantation

“True” bifurcation lesion with an important SB > 5-10 mm lesion length

Low risk of losing the SB after MB stenting


Major concerns regarding the SB after MB stenting

MB stenting followed by planned SB implantation



Mini DK-CRUSH

Inv. MB stenting across SB



Always end with a Final Kiss !




## **Mechanisms of stent thrombosis: strut / flow interactions**


# Late Thrombosis After 2 Versus 1 DES in the Treatment of Coronary Bifurcations. Meta-analysis of Randomized and Observational Studies

**A**

DES Thrombosis



# Simulation of the microscopic process during initiation of stent thrombosis



Streamlines (left panels) and shear stress contours (right panels) for different strut heights, including 50 (top panels), 100 (middle panels), and 200  $\mu\text{m}$  (bottom panels)

# Pathological Findings at Bifurcation Lesions: Impact of Flow Distribution on Atherosclerosis and Arterial Healing After Stent Implantation

	DES (12 Lesions, 17 Stents)		p Value
	Flow Divider	Lateral	
Neointimal thickness (mm)	0.07 (0.03-0.15)	0.17 (0.09-0.23)	0.001
Fibrin deposition (% struts)	60 (21-67)	17 (0-55)	0.01
Uncovered struts (% struts)	40 (16-76)	0 (0-15)	0.001

# Correlates and outcomes of late and very late DES thrombosis: results from DESERT

## Clinical and Angiographic Correlates of Late/Very Late Stent Thrombosis

Variable	Clinical, OR (95% CI)	Angiographic	Combined, OR (95% CI)
Age	<b>0.964 (0.95-0.98)</b>	*	<b>0.793 (0.96-0.99)</b>
Hypertension	0.757 (0.51-1.12)	*	0.863 (0.56-1.34)
Body mass index	0.979 (0.95-1.01)	*	0.981 (0.95-1.01)
ACS/NSTEMI	1.084 (0.70-1.67)	*	0.831 (0.54-1.28)
Left anterior descending lesion	1.107 (0.77-1.59)	<b>1.671 (1.21-2.32)</b>	1.302 (0.87-1.96)
Current smoker	<b>1.890 (1.26-2.85)</b>	*	<b>1.633 (1.05-2.53)</b>
STEMI or thrombus (QCA)	1.059 (0.62-1.80)	<b>1.486 (1.03, 2.14)</b>	1.062 (0.66-1.71)
African American	<b>2.346 (1.21-4.54)</b>	*	1.612 (0.65-3.99)
Diabetes	0.915 (0.60-1.40)	*	1.021 (0.65-1.60)
Renal insufficiency	1.019 (0.50-2.09)	*	*
No. of diseased vessels	<b>1.313 (1.05-1.65)</b>	*	<b>1.712 (1.32-2.22)</b>
Type C lesion (QCA)	*	0.939 (0.54-1.63)	<b>2.188 (1.38-3.47)</b>
Final reference vessel diameter, mm	*	1.190 (0.77-1.85)	1.436 (0.84-2.44)
Acute gain, mm	*	0.982 (0.64-1.51)	1.013 (0.64-1.61)
Final in-stent diameter stenosis	*	<b>1.021 (1.00-1.04)</b>	1.014 (0.99-1.04)
Total stented length	<b>1.015 (1.00-1.03)</b>	1.022 (1.00-1.05)	<b>0.977 (0.97-0.99)</b>
Bypass graft lesion	<b>3.306 (1.18-9.27)</b>	<b>3.900 (1.55-9.84)</b>	1.997 (0.60-6.70)
Lesion length (QCA)	*	0.999 (0.97-1.03)	*
Overlapping stents	<b>1.757 (1.18-2.61)</b>	*	<b>2.220 (1.34-3.69)</b>

- Minimize overlapping (carena...)
- Stent deployment
- Wall apposition
- Imaging


**What are the objectives of bifurcation stenting ?**

## Objectives of bifurcation lesion treatment ?



- Suppress ischemia
- Suppress stenosis
- Obtain « protective » diameters
- On the long term: prevent neo atheroma?



# Flow Patterns and Spatial Distribution of Atherosclerotic Lesions in Human Coronary Arteries




**Low wall shear stress =  
proatherogenic**



Asakura, Circulation Research 1990; 66:1045-1066

# Evaluation of Local Flow Conditions in Jailed Side Branch Lesions Using Computational Fluid Dynamics

Area of low WSS (<4 Pa) in 8-computational bifurcation models



## Bifurcation lesion treatment principles

- 1. Protection only for non clinically relevant SB (non left main, length, diameter ...)**
- 2. Limit the number of stents (provisional, FFR)**
- 3. Single stent layer, well apposed**
- 4. Respect the original anatomy**